Multibagger pharma penny stock under Rs 15 hit upper circuit after completing export-sourcing orders aggregating to Rs 299.91 crore

DSIJ Intelligence-1 / 08 Jul 2025/ Categories: Multibaggers, Penny Stocks, Trending

Multibagger pharma penny stock under Rs 15 hit upper circuit after completing export-sourcing orders aggregating to Rs 299.91 crore

The company has a market cap of Rs 139 crore and the stock has given multibagger returns of 136 per cent from its 52-week low of Rs 5.24 per share.

Welcure Drugs & Pharmaceuticals Limited has successfully completed export-sourcing assignments worth a total of Rs 299.91 crore during Q1 FY2025–26, as disclosed in a post-facto intimation dated July 8, 2025. The company acted solely as a procurement agent and earned a fixed 5 per cent commission on these transactions. The export orders were distributed equally across seven overseas clients, each valued at Rs 42.80 crore. These clients include Gyandevi Export (Rs 42.80 crore, settled in full), Ravina International (Rs 42.80 crore, with advance received and balance due by July 31, 2025), Megh Mani International (Rs 42.80 crore, settled in full), Giant Exim (Rs 42.80 crore, advance received), Sakalchand Manilal & Co. (Rs 42.80 crore, LC realised), Shree Kalbadevi Exim (Rs 42.80 crore, LC realised) and Maa Shakti Exports (₹42.80 crore, LC realised).

None of the counterparties involved are related parties and the transactions were carried out in the ordinary course of business. The commission income will be recognised on receipt, in line with Ind AS 115. Welcure emphasised that the cost of goods was directly settled by the buyers and no equity or debt instruments were involved in the process, reaffirming its debt-free status.

DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.

Welcure Drugs & Pharmaceuticals Ltd, incorporated in 1992, previously focused on the manufacturing of pharmaceutical products. Their business encompassed the production and marketing of a wide range of pharmaceutical formulations, including tablets, capsules and dry syrups. The company's product portfolio included various therapeutic categories such as antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquillizers, sedatives and gastrointestinal medications.

On Tuesday, shares of Welcure Drugs & Pharmaceuticals Ltd hit a 5 per cent upper circuit to Rs 12.35 per share from its previous closing of Rs 11.77 per share. The company has a market cap of Rs 139 crore and the stock has given multibagger returns of 136 per cent from its 52-week low of Rs 5.24 per share.

Disclaimer: The article is for informational purposes only and not investment advice.